November 19th, 2015
Immunovia’s share issue oversubscribed five times prior to listing on the Nasdaq First North in Stockholm

Immunovia’s share issue oversubscribed five times prior to listing on the Nasdaq First North in Stockholm

The new share issue of Immunovia AB’s (publ) (“Immunovia” or the “Company”) prior to listing on Nasdaq First North was subscribed to SEK 305 million, representing a subscription rate of 500 percent. The issue provides the Company with SEK 60 million before transaction costs and about 1100 new shareholders. First day of trading of the Company’s shares on Nasdaq First North in Stockholm is expected to be 1 December 2015.

Immunovia has developed an innovative technology for cancer diagnosis and the new funds will now finance commercialization of the Company’s test for diagnosing pancreatic cancer. The technology has the potential to provide the world’s first blood-based cancer diagnostic tests in this area. The funds will also be used to further develop Immunovia’s upcoming tests for other cancers and for the autoimmune disease lupus (SLE).

The subscription period for Immunovia’s share issue expired on November 16, 2015. Already before the subscription period began, a number of existing and new investors, including the Bank of Åland’s Fund Management Division together with several international investors, had committed to subscribe for shares in the issue totaling close to SEK 50 million or approximately 83 per cent of the offer. These investors were then given priority when shares were allocated.  However, the overall goal of the share issue remained to obtain a broad distribution of shares among the public in Sweden in order to allow regular and liquid trading of Immunovia’s shares on Nasdaq First North.

After the new share issue has been registered at Bolagsverket (the Swedish Companies Registration Office), the total number of shares in Immunovia increased by 3,245,000 to 14,291,216 representing an increase of the share capital and votes of 29 percent.

Advisor
Vator Securities is the financial advisor and Baker & McKenzie is the legal advisor to the Company in connection with the new share issue and listing on Nasdaq First North.

For more information, please contact:
Mats Grahn, CEO, Immunovia
Phone: + 46-70-532 02 30
E-mail: mats.grahn@immunovia.com

 
About Immunovia

Immunovia AB was founded in 2007 by scientists from the Department of Immunotechnology at Lund University and CREATE Health – A Strategic Centre for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher a large amount of information in the blood and translate it into clinically useful tools to diagnose complex diseases such as cancer and to do this earlier and more accurately than previously possible. Immunovia’s core technology platform, IMMray™, is based on antibody microarray analysis. The company now performs clinical validation studies for commercialization of IMMray™ PanCan-d, which has the potential to become the first blood-based test for early diagnosis of cancer of the pancreas.